Live Breaking News & Updates on Cutaneous Oncology Programs

Stay updated with breaking news from Cutaneous oncology programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics . ....

United States , Williamm Scholl , Ellen Lubman , Michael Atkins , Melanoma Research Alliance Medical Advisory Panel , Society For The Immunotherapy Of Cancer , Verge Scientific Communications , Professor At Harvard Medical School , Advisory Council , Cancer Center , Werewolf Therapeutics Inc , Company Contact , Academy Of Immunooncology , Werewolf Board , Deputy Director , Georgetown Lombardi Comprehensive Cancer Center , Vice Chair , Georgetown University Medical , Harvard Medical , Biologic Therapy , Cutaneous Oncology Programs , Beth Israel Deaconess Medical Center , Harvard Skin Cancer , Kidney Cancer , Scientific Advisory Council , Melanoma Research Foundation ,

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

WATERTOWN, Mass., Sept. 11, 2023 Werewolf Therapeutics, Inc. , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate. ....

Josh Rappaport , Michaelb Atkins , Williamm Scholl , Michael Atkins , Ellen Lubman , Division Of Hematology Oncology , Advisory Committee , Lombardi Immunotherapy Initiative , Werewolf Therapeutics Inc , Beth Israel Deaconess Medical Center , Globenewswire Inc , Scientific Advisory Council , Georgetown University , Company Or Werewolf Nasdaq , Harvard Medical School , Scientific Communications , Tufts Medical Center , Division Of Hematology , Georgetown Lombardi Comprehensive Cancer Center , Medstar Georgetown University Hospital , Chair Of The Melanoma Research Foundation , Department Of Oncology , Society For Immunotherapy Of Cancer , Vice Chair , Medical Center , Israel Deaconess Medical Center ,

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Michaelb Atkins , Ellen Lubman , Josh Rappaport , Michael Atkins , Williamm Scholl , Georgetown Lombardi Comprehensive Cancer Center , Lombardi Immunotherapy Initiative , Advisory Committee , Oncology At Medstar Georgetown University Hospital , Department Of Oncology , Division Of Hematology Oncology , Tufts Medical Center , Professor At Harvard Medical School , Beth Israel Deaconess Medical Center , Werewolf Therapeutics Inc , Company Or Werewolf Nasdaq , Division Of Hematology , Scientific Communications , Society For Immunotherapy Of Cancer , Department Of Oncology At Georgetown University , Vice Chair , Georgetown University , Harvard Medical School , Deputy Chief , Biologic Therapy , Cutaneous Oncology Programs ,

Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCC

David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.
....

Davidf Mcdermott , Beth Israel Deaconess Medical Center , Harvard Medical School , Biologic Therapy , Cutaneous Oncology Programs , Genitourinary Cancers , Onclive Tv , Phase 1 2 Litespark 024 Trial , Renal Cell Carcinoma ,

LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC

David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial. ....

United States , Dana Farber Cancer Institute , Davidf Mcdermott , Harvard Medical School , Kidney Cancer Research Summit Mcdermott , Kidney Cancer Research Summit , Cancer Research Summit Mcdermott , Biologic Therapy , Cutaneous Oncology Programs , Beth Israel Deaconess Medical Center , Cancer Research , The Combination Of Belzutifan With Palbociclib , Patients With Pretreated Advanced Renal Cell Carcinoma , Litespark 024 Trial ,